Cargando…

Pharmakotherapie und intensivmedizinische Aspekte des Status epilepticus: Update 2020/2021

Focused treatment of epileptic emergencies, and in particular status epilepticus (SE), require a reliable differentiation of epileptic syndromes. In these cases, and especially in cases with predominant non-motor symptoms, clinical and electroencephalographic expertise is necessary. In 2020 the Germ...

Descripción completa

Detalles Bibliográficos
Autores principales: Saitov, Gabrielė, Müller, Annekatrin, Bastian, Börge, Michalski, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492596/
https://www.ncbi.nlm.nih.gov/pubmed/34212230
http://dx.doi.org/10.1007/s00101-021-01000-y
_version_ 1784578947168600064
author Saitov, Gabrielė
Müller, Annekatrin
Bastian, Börge
Michalski, Dominik
author_facet Saitov, Gabrielė
Müller, Annekatrin
Bastian, Börge
Michalski, Dominik
author_sort Saitov, Gabrielė
collection PubMed
description Focused treatment of epileptic emergencies, and in particular status epilepticus (SE), require a reliable differentiation of epileptic syndromes. In these cases, and especially in cases with predominant non-motor symptoms, clinical and electroencephalographic expertise is necessary. In 2020 the German guidelines for the management of SE were updated, which adhere to a strict stage-based treatment algorithm. The staged approach includes the administration of benzodiazepines, antiepileptic drugs and anesthetic agents. So far, efforts failed to determine the most effective and safest antiepileptic drug without interaction potential. Therefore, for the differentiated treatment of SE, individual pre-existing medical conditions and concomitant circumstances must be considered, added by the experience of the medical team. Therapeutic interventions especially for refractory forms of SE have been shown to be complex with relevant implications concerning intensive care aspects. Consequently, the modern treatment strategy of SE is characterized by an interdisciplinary approach. Future research is needed to define the optimal treatment of non-convulsive SE, in particular regarding the time point and degree of treatment escalation with associated ethical considerations.
format Online
Article
Text
id pubmed-8492596
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-84925962021-10-15 Pharmakotherapie und intensivmedizinische Aspekte des Status epilepticus: Update 2020/2021 Saitov, Gabrielė Müller, Annekatrin Bastian, Börge Michalski, Dominik Anaesthesist Klinische Pharmakologie Focused treatment of epileptic emergencies, and in particular status epilepticus (SE), require a reliable differentiation of epileptic syndromes. In these cases, and especially in cases with predominant non-motor symptoms, clinical and electroencephalographic expertise is necessary. In 2020 the German guidelines for the management of SE were updated, which adhere to a strict stage-based treatment algorithm. The staged approach includes the administration of benzodiazepines, antiepileptic drugs and anesthetic agents. So far, efforts failed to determine the most effective and safest antiepileptic drug without interaction potential. Therefore, for the differentiated treatment of SE, individual pre-existing medical conditions and concomitant circumstances must be considered, added by the experience of the medical team. Therapeutic interventions especially for refractory forms of SE have been shown to be complex with relevant implications concerning intensive care aspects. Consequently, the modern treatment strategy of SE is characterized by an interdisciplinary approach. Future research is needed to define the optimal treatment of non-convulsive SE, in particular regarding the time point and degree of treatment escalation with associated ethical considerations. Springer Medizin 2021-07-01 2021 /pmc/articles/PMC8492596/ /pubmed/34212230 http://dx.doi.org/10.1007/s00101-021-01000-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Klinische Pharmakologie
Saitov, Gabrielė
Müller, Annekatrin
Bastian, Börge
Michalski, Dominik
Pharmakotherapie und intensivmedizinische Aspekte des Status epilepticus: Update 2020/2021
title Pharmakotherapie und intensivmedizinische Aspekte des Status epilepticus: Update 2020/2021
title_full Pharmakotherapie und intensivmedizinische Aspekte des Status epilepticus: Update 2020/2021
title_fullStr Pharmakotherapie und intensivmedizinische Aspekte des Status epilepticus: Update 2020/2021
title_full_unstemmed Pharmakotherapie und intensivmedizinische Aspekte des Status epilepticus: Update 2020/2021
title_short Pharmakotherapie und intensivmedizinische Aspekte des Status epilepticus: Update 2020/2021
title_sort pharmakotherapie und intensivmedizinische aspekte des status epilepticus: update 2020/2021
topic Klinische Pharmakologie
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492596/
https://www.ncbi.nlm.nih.gov/pubmed/34212230
http://dx.doi.org/10.1007/s00101-021-01000-y
work_keys_str_mv AT saitovgabriele pharmakotherapieundintensivmedizinischeaspektedesstatusepilepticusupdate20202021
AT mullerannekatrin pharmakotherapieundintensivmedizinischeaspektedesstatusepilepticusupdate20202021
AT bastianborge pharmakotherapieundintensivmedizinischeaspektedesstatusepilepticusupdate20202021
AT michalskidominik pharmakotherapieundintensivmedizinischeaspektedesstatusepilepticusupdate20202021